Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab

Research output: Contribution to journalArticlepeer-review


Purpose: The purpose of this study was to report functional and morphologic retinal changes after intravitreal injections of 0.5 mg ranibizumab in patients with myopic neovascular membrane (choroidal neovascularization). Methods: This is a case review of 11 consecutive patients with myopic choroidal neovascularization who received intravitreal injections of ranibizumab at monthly intervals. Serial changes in best-corrected visual acuity, optical coherence tomography, fluorescein angiography, and microperimetry (Nidek MP1, Nidek, Padova, Italy) are presented. Results: Mean baseline best-corrected visual acuity was 59.82 ± 17.50 Early Treatment Diabetic Retinopathy Study letters. After a follow-up of 36 weeks, mean visual acuity improved to 66.72 ± 17.3 with a mean change of 6.91 letters. Mean baseline retinal sensitivity was 6.02 ± 1.9 dB. After 36 weeks, mean sensitivity improved to 8.3 ± 2.4 dB with a mean change of 2.3 dB. The fixation stability improved from 45.5% to 72.7%. All patients also had complete resolution of subretinal fluid, mean optical coherence tomography central retinal thickness was reduced from 244.64 ± 39.3 μm to 191.36 ± 27.3 μm at 36 weeks, and fluorescein angiography at 36 weeks showed absence of leakage in all patients. Conclusion: Intravitreal ranibizumab injections seemed to positively influence retinal functional status in patients with myopic choroidal neovascularization.

Original languageEnglish
Pages (from-to)413-417
Number of pages5
Issue number3
Publication statusPublished - Mar 2010


  • Anti-VEGF drugs
  • Choroidal neovascularization
  • CNV
  • Microperimetry
  • Myopic CNV
  • Pathologic myopia
  • Ranibizumab
  • Retinal sensitivity
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Microperimetric retinal changes in myopic choroidal neovascularization treated with intravitreal ranibizumab'. Together they form a unique fingerprint.

Cite this